Alexander S.
- Country
- Germany
- Department
- Abteilung für Hämatologie, Onkologie und Palliativmedizin
Research Overview
- Efficacy and Safety Comparison of Obinutuzumab-Venetoclax vs. Obinutuzumab-Chlorambucil in Untreated CLL with Comorbidities
- A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab versus fixed-duration Venetoclax plus Ibrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL) - CLL17
- Randomized European Trial of Autologous Transplantation with Rituximab, Ibrutinib, and Ara-C Induction in Generalized Mantle Cell Lymphoma
Data & Insights
Has run more than one trial at 82 of 299 partner sites.
Specializations
Hematologic Oncology
This investigator specializes in treating chronic lymphocytic leukemia (CLL), with particular emphasis on developing innovative therapeutic approaches for previously untreated patients.
- First-line CLL Treatment Strategies
- Novel Therapeutic Combinations
- Treatment of Treatment-Naïve CLL
The investigator's work encompasses targeted therapies including obinutuzumab and venetoclax combinations.
High-Risk Hematologic Malignancies
Expertise in managing high-risk hematologic conditions, particularly focusing on CLL cases with specific genetic alterations and complex presentations.
- 17p-Deletion Cases
- TP53-Mutation Management
- Complex Karyotype Conditions
The research extends to novel therapeutic approaches using acalabrutinib and combination strategies.
Lymphoma Studies
Dedicated research in mantle cell lymphoma treatment, incorporating various therapeutic modalities and maintenance strategies.
- Autologous Transplantation
- Combination Therapy Approaches
- Maintenance Treatment Protocols
Focus includes investigating rituximab and ibrutinib based treatment regimens.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.